# Minimal Residual Disease Monitoring > Minimal residual disease monitoring for NEET-PG Pathology: flow cytometry, clone-specific PCR and NGS sensitivities with ELN, BFM and CML thresholds. - Canonical URL: https://prepelephant.com/topics/neet-pg/pathology/minimal-residual-disease-monitoring - Exam / course: NEET-PG · Subject: Pathology - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Minimal Residual Disease Monitoring", PrepElephant, https://prepelephant.com/topics/neet-pg/pathology/minimal-residual-disease-monitoring ## Direct answer Remission, as traditionally declared, is a weaker statement than it sounds: conventional microscopy resolves about one leukaemic cell in five hundred, while minimal residual disease assays find one in ten thousand and below. MRD monitoring quantifies that residue by three platforms — multiparameter and next-generation flow cytometry, clone-specific quantitative PCR of immunoglobulin/TCR rearrangements or fusion transcripts, and error-corrected next-generation sequencing with sensitivities to one in a million. Its clinical weight is now formalised: end-induction MRD assigns risk groups in childhood ALL, NPM1 burden of 0.1% or more after induction flags relapse risk in AML per ELN 2022, and molecular milestones (MMR, MR4.5) drive treatment-free remission decisions in CML. ## What you must remember - **Sensitivity ladder:** conventional 4-colour flow around 10^-4; next-generation flow (EuroFlow-type) 10^-5 to 10^-6; allele-specific oligonucleotide PCR 10^-4 to 10^-5; error-corrected NGS platforms to 10^-6 — each assay's negativity is assay-dependent. - **Flow targets:** leukaemia-associated immunophenotypes (LAIP) defined at diagnosis, or the different-from-normal approach; aberrant marker combinations such as CD19-positive myeloid blasts or CD10-dim aberrant B precursors are the tracked signatures. - **PCR targets:** patient-specific IgH/TCR junctional sequences for ALL and lymphoma (requires a diagnostic sample for primer design), fusion transcripts BCR-ABL1 and PML-RARA, and NPM1 mutations in AML. - **ALL thresholds:** end-induction MRD of 10^-4 or above assigns high risk in BFM-type protocols; MRD-guided intensification and blinatumomab for persistent or re-emergent MRD are the modern responses. - **AML (ELN 2022):** MRD by multiparameter flow or NGS; NPM1 variant burden of 0.1% or more after induction identifies relapse risk and steers transplant discussions. - **CML molecular ladder:** international-scale BCR-ABL1 — major molecular response at 0.1%, MR4 at 0.01%, MR4.5 at 0.0032%; deep responses underpin treatment-free remission attempts. - **Myeloma:** next-generation flow or clonotype sequencing negativity correlates with prolonged progression-free survival; peripheral blood MRD is an emerging sampling route. - **Pitfalls:** haemodilution, sample timing, lineage switch at relapse, clonal evolution, and interpreting negativity from an insensitive assay. ## A day-33 marrow, read properly A four-year-old with B-ALL finishes induction and the protocol demands a marrow. Flow runs the eight-colour tube: within the CD45-dim gate, 0.03% of nucleated cells show the diagnostic aberrancy — CD10 positive, CD19 dim, CD45 dim, aberrant CD13. The arithmetic decides the week: 0.03% is 3 x 10^-4, above the 10^-4 threshold, so MRD-positive — the child is reclassified to higher risk, therapy intensifies, and the family meeting acquires new content. Had the laboratory run only a four-colour legacy panel, the sensitivity floor of 10^-4 might have called the same marrow "negative" while carrying an unresolvable question; the assay choice was made months earlier, at diagnosis, when the LAIP was defined. This is MRD in one sentence: a longitudinal measurement whose meaning depends entirely on the sensitivity chosen at baseline and the timing chosen by protocol. ## Where students slip The commonest error is quoting "MRD negative" without the platform — negativity at 10^-4 is a different claim from negativity at 10^-6, and relapses occur between them. The second slip is PCR design logic: patient-specific IgH/TCR primers require the diagnostic sample, so a consultation that arrives mid-treatment cannot be assayed that way. Third, students treat MRD as an ALL-only concept; ELN 2022 embeds it in AML and myeloma practice equally. In vivas, the quotable specifics are the sensitivity ladder in order, the NPM1 0.1% threshold, the CML MR4.5 figure of 0.0032%, and the observation that peripheral blood sampling may one day replace some marrows — each a sentence that shows the topic is understood as a system, not a test. ## Frequently asked questions ### What is the sensitivity of next-generation flow cytometry? About 10^-5, extendable toward 10^-6 with EuroFlow-style standardised tubes — an order beyond conventional four-colour flow. ### Why does clone-specific PCR need the diagnostic sample? IgH/TCR junction sequences are unique to the patient's clone; primers for MRD tracking must be designed from the baseline sample. ### What MRD threshold matters in childhood ALL? End-induction MRD of 10^-4 or above assigns high-risk status and triggers treatment intensification in BFM-type protocols. ### What is the NPM1 MRD threshold in AML? A variant allele fraction of 0.1% or more after induction identifies elevated relapse risk per ELN 2022 guidance. ### What does MR4.5 mean in CML? A BCR-ABL1 transcript level of 0.0032% on the international scale — deep molecular response relevant to treatment-free remission.